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Abstract.
Background: Cholinesterase inhibitors represent three of the four treatments for Alzheimer’s disease (AD), and target the
pathological reduction of acetylcholine levels. Here we aimed to study the role of other neurotransmitter pathways in AD
pathology.
Objective: This study aimed to determine associations between AD pathology at both symptomatic and asymptomatic stages
of disease progression, and the metabolism of a range of non-cholinergic neurotransmitters.
Methods: Tissue samples were obtained from three groups, controls, AD, and ‘asymptomatic AD’ (ASYMAD), i.e., cogni-
tively normal individuals that had significant AD neuropathology. Three brain areas were studied, the middle frontal gyrus
(MFG), the inferior temporal gyrus (ITG), and the cerebellum.
Results: 12 of 15 metabolites involved in neurotransmitter metabolism were shown to be associated with AD pathology.
Decreases in dopamine were most pronounced in the MFG with lower levels seen in the ASYMAD group compared to control
(FC = 0.78,p = 2.9 × 10–2). In the ITG significant changes were seen in GABAergic and serotonin metabolism between control
and AD patients; however, these changes were not seen between control and ASYMAD individuals.
Conclusion: These results indicate that dopamine could be depleted in brains with AD pathology but intact cognition, while
an imbalance of several neurotransmitters is evident in the brains of AD patients.
Keywords: Asymptomatic Alzheimer’s disease, brain, metabolomics, neurotransmitters
INTRODUCTION
Dementia is a devastating illness for both patients
and their families, with Alzheimer’s disease (AD)
estimated to account for up to 80% of total demen-
tia cases. The ‘World Alzheimer’s Report 2015’
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Science, University of Cambridge, Pathology building level 4,
Addenbrooke’s Hospital, Cambridge, CB2 0QQ, UK. Tel.: +44
7708953183; E-mail: sgs44@medschl.cam.ac.uk.
estimates that there are approximately 46 million AD
patients worldwide, with this number expected to rise
to over 130 million by the middle of the century [1].
As well as a significant human cost, AD also repre-
sents a major financial burden with worldwide costs
related to AD expected to reach $1 trillion dollars in
2018 [1].
Cholinesterase inhibitors make up three of the
four approved AD treatments (donepezil, rivastig-
mine, and galantamine), making inhibition of
acetylcholinesterase the leading therapeutic strategy
for the treatment of AD symptoms [2, 3]. There
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is a significant body of literature suggesting that
the cognitive deficits associated with AD are the
result of lower levels of acetylcholine in the brain
resulting from dysfunction of cholinergic neurons
[4–6]. The role of non-cholinergic neurotransmit-
ter systems in AD pathogenesis has received less
attention. While levels of non-cholinergic neurotrans-
mitters in the brain have been associated with AD
pathology [7–11], their role in mediating the onset
of symptoms is less well understood. In this study,
we analyzed data from a non-targeted metabolomics
platform to compare differences in neurotransmitters
and neurotransmitter-associated metabolite levels in
brain tissue samples from the autopsy cohort of the
Baltimore Longitudinal Study of Aging (BLSA).
We studied three groups of BLSA participants, AD
patients, cognitively normal controls, and ‘asymp-
tomatic AD’ (ASYMAD), i.e., individuals with
significant AD neuropathology at death but with no
evidence of cognitive impairment during life. We
studied three distinct brain regions in these individ-
uals that are differentially affected pathologically:
the inferior temporal gyrus (ITG) which is vulner-
able to neurofibrillary tau tangles, the middle frontal
gyrus (MFG) which is susceptible to the accumula-
tion amyloid- plaques, and the cerebellum which is
resistant to classical AD pathology [12]. This study
aimed to determine if non-cholinergic neurotransmis-
sion might also be dysregulated in the pathology of
AD. We also wanted to see if the metabolism of
neurotransmitters was being modulated differently
in different brain regions with differing levels of
amyloid- and tau.
METHODS
Chemicals and reagents
All solvents, water, acetonitrile, methanol, ammo-
nium formate, formic acid, and methyl tertiary butyl
ether, were LC-MS grade purchased from Sigma-
Aldrich. Internal standards L-serine 13C315 N (95%
pure) and L-valine 13C515 N (95% pure) were pur-
chased from Sigma-Aldrich. In vial dual extractions
were performed in amber glass HPLC vials with
400l fixed inserts (Chromacol: Welwyn Garden
City, UK).
Sample information
The BLSA is a prospective, ongoing cohort study
of community-dwelling volunteer participants in
Baltimore begun in 1958. As such, it is among the
largest and longest-running longitudinal studies of
aging in the United States [13, 14]. In general, at
the time of entry into the study, participants had no
physical or cognitive impairment. Detailed exami-
nations, including neuropsychological assessments
and neurological, laboratory, and radiological eval-
uations, were conducted every 2 years. Since 2003,
participants older than 80 years have received yearly
assessments. Written informed consent was obtained
at each visit, and the study was approved by the local
Institutional Review Board and the National Insti-
tute on Aging. After each visit, cognitive status was
considered relying on information from neuropsy-
chological tests as well as clinical data as described
previously [15]. Diagnoses of dementia and AD were
based on DSM-III-R [16] and the NINCDS-ADRDA
criteria [17], respectively.
Brain tissue samples were collected through the
autopsy sample of the BLSA. The autopsy program
of the BLSA was initiated in 1986. We have previ-
ously described the study protocol in detail. Briefly,
the mean age at death in the autopsy sample is
88.3 ± 7.3 years (range 69.3–103.2), and the mean
interval between the last evaluation and death is
8.7 ± 6.7 months [18]. As reported previously, the
autopsy subsample is not significantly different from
the BLSA cohort as a whole in terms of the rates of
dementia and clinical stroke [19]. Table 1 describes
the demographic characteristics of the participants
whose brain tissue samples were used in this study,
with the same sample set having been used previ-
ously in the study of fatty acid metabolism described
in Snowden et al. [20].
Sample preparation and LC-MS analysis
Thirteen of the fifteen metabolites described in
this paper (tyrosine, L-DOPA, dopamine, aminobu-
tanal, arginine, aspartate, GABA, glutamate, glu-
tamine, guanidinobutanoate, glycine, guanosine, and
ornithine) were measured on an in-house platform
that is described in detail in Ebshiana et al. [21].
Briefly 20l of methanol and 5l of internal standard
solution (2.5 mM L-serine 13C315 N and L-valine
13C515 N in 4:1 methanol:water) was added per mil-
ligram of tissue prior to homogenization. Tissue was
homogenized using a 4-mm stainless steel ball bear-
ing and Tissuelyzer (Qiagen) in 10 cycles of 30 s at
25 Hz. Subsequently 50l of homogenate was trans-
ferred to a HPLC vial (400l fixed insert), to which
10l water and 250l of methyl-tertiary butyl ether
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Table 1
Clinical characteristics of study participants
Control Asymptomatic AD Alzheimer’s Disease
Participants 14 15 14
Sex (female/male) 4/10 5/10 7/7
Age at death (y)∗ 82.6 ± 11.0 (64.2–99.2) 89.2 ± 7.9 (71.9–96.4) 87.9 ± 8.9 (62.9–98.7)
MMSE† 27.8 ± 2.4 29.0 ± 0.9∗ 23.0 ± 6.9∗
PMI (h)‡ 16.9 ± 6.4 (7.0–28.0) 14.8 ± 8.1 (2.0–33.0) 14.7 ± 6.0 (3.0–23.0)
Cholinesterase/NMDA agonist usage 0/0 0/0 2/0
∗Values are reported as the mean ± standard deviation, and range, †values are reported as the mean ± standard deviation; ‡values are reported
as the mean ± standard deviation, and range. MMSE; Mini-Mental State Examination, NMDA, N-methyl-D-aspartate, PMI, postmortem
interval.
were added prior to vortexing at room temperature
for 1 h. Following this, 40l of water containing
0.15 mM ammonium formate was added, and sam-
ples were then spun at 2500× g for 30 min at 4◦C.
Prior to analysis, samples were stored at –20◦C with
samples and QCs stored for no longer than 7 days
prior to analysis.
Samples were analyzed on a Waters Acquity ultra
performance liquid chromatography (UPLC) system
coupled to a Waters premier quadrupole time-of-
flight (Q-ToF) mass spectrometer (Waters, Millford,
MA, USA). Briefly, 5l of the aqueous phase was
injected on a Merck Sequant Zic-HILIC column
(150 × 4.6 mm, 5m particle size) coupled to a
Merck Sequant guard column (20 × 2.1 mm). The
gradient was performed over 40 min at room temper-
ature with a flow rate of 0.3 ml/min using 0.1% formic
acid in water (mobile phase A) and 0.1% formic
acid in acetonitrile (mobile phase B). The gradient
started at 80% mobile phase B, followed by a linear
reduction to 20% B at 30 min followed by 10 min re-
equilibration at the initial conditions. Mass spectral
data was acquired between 75–1000 daltons, and data
was collected in centroid mode with an acquisition
time of 0.1 s per scan.
Additional metabolite analysis
Data on the abundance of serotonin and trypto-
phan were acquired using the Biocrates platform.
To extract metabolites from brain tissue, sam-
ples were homogenized using Precellys® with
ethanol phosphate buffer. Samples were then cen-
trifuged and the supernatant was used for analysis.
The fully automated assay was based on liquid
chromatography-tandem mass spectrometry (LC-
MS/MS; amino acids) using a SCIEX 4000 QTrap®
mass spectrometer (SCIEX, Darmstadt, Germany)
with electrospray ionization. Brain tissue concen-
tration was absolute concentration expressed as
nmol/mg tissue.
Statistical methods and pathway mapping
To compare the abundance of neurotransmitters
and their associated metabolites among the three
groups (CN, ASYMAD, and AD), we used general-
ized linear models (GLM) performed in ‘R’ (version
3.4.2), with all the calculated models corrected for
both age and sex. With the three patient groups poten-
tially representing distinct biological phenotypes, we
decided to focus on binary comparisons between
groups. The relationship of metabolite abundance to
measures of cognitive performance was assessed by
comparing the metabolite abundance with measures
of cognition, the Mini-Mental State Examination
(MMSE), Boston naming test, and Benton visual
retention score, this was done again using GLM per-
formed in ‘R’ (version 3.4.2).
Pathway mapping was performed in Cytoscape
(version 3.4.0) with the architecture of the displayed
pathways determined by metabolic interactions
defined in the Kyoto Encyclopedia of Genes and
Genomes (KEGG). Within the network, node size is
directly proportional to the fold change in metabo-
lite abundance between control and AD groups, with
edge thickness directly proportional to the partial cor-
relation of the two nodes it is connecting. The partial
correlation coefficients were calculated using Pear-
son’s correlation to compare the abundance of the two
metabolites in all samples in the given brain region.
RESULTS
Analysis of control versus ASYMAD groups
The abundance of all fifteen metabolites were com-
pared between control and ASYMAD individuals
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Fig. 1. Showing pathway analysis of the association of neurotransmitter metabolism to Alzheimer’s disease in human brain using the
comparison of control and AD individuals. Metabolites significantly increased in abundance (p < 0.05) and shown as green triangles and
metabolites significantly decreased in abundance (p < 0.05) and shown as red chevrons with the size representing the magnitude of the
change. Grey circles represent metabolites that were not significantly associated with disease. A) shifts observed in the cerebellum, B) shifts
observed in the inferior temporal gyrus, C) shifts observed in the middle frontal gyrus.
(Fig. 1, Table 2, Supplementary Figure 1). The
only neurotransmitter that had a significantly altered
abundance was dopamine which was decreased in
the MFG (FC = 0.78, p = 2.9 × 10–2). In the ITG,
aminobutanal, aspartate, and guanosine, which are all
involved in the metabolism of GABA, were decreased
in abundance in the ASYMAD patients (FC = 0.86
& p = 4.3 × 10–2, FC = 0.83 & p = 2.7 × 10–2, and
FC = 0.72 & p = 3.3 × 10–2, respectively) (Fig. 1,
Table 2, Supplementary Figure 1). All other mea-
sured metabolites showed no significant difference
between control and ASYMAD groups in any of the
brain regions analyzed.
Analysis of control versus AD groups
In the comparison of control versus AD groups,
changes were observed mainly in the ITG. In the
ITG, excitatory neurotransmitters glutamate and
aspartate exhibited a lower abundance (p < 0.05) in
AD patients. Also, in the ITG, inhibitory neuro-
transmitters glycine and serotonin were decreased,
while GABA was increased (p < 0.05). A number
of neurotransmitter precursors were also increased:
ornithine, arginine, and tryptophan (all p < 0.05),
while guanidobutanoate, guanosine, and aminobu-
tanal were all significantly decreased (all p < 0.05)
in the ITG of AD patients (Fig. 1, Table 2, Supple-
mentary Figure 1). In the MFG, dopamine precursors
L-DOPA and tyrosine were the only metabolites
to be increased with disease. An increase in L-
DOPA was the only significant difference observed
in the cerebellum (Fig. 1, Table 2, Supplementary
Figure 1).
Analysis of ASYMAD versus AD groups
In the comparison of AD versus ASYMAD, two
changes were observed in the MFG: GABA was
increased (FC = 1.23, p = 1.3 × 10–2) and guanidobu-
tanoate was decreased (FC = 0.84, p = 1.9 × 10–2).
In the ITG, guanidobutanoate and glycine were
decreased (FC = 0.69, p = 1.2 × 10–4, FC = 0.74,
p = 5.0 × 10–3, respectively) (Table 2, Supplemen-
tary Figure 1). There were no other significant
differences observed between ASYMAD and AD
groups in any of the analyzed brain regions.
Correlation of metabolite abundance and
cognitive performance
Analysis to investigate the relationship between
metabolite abundance and cognitive performance
showed that dopamine, tryptophan, aspartate,
aminobutanal, GABA, and guanidobutanoate pos-
itively correlated with MMSE (p < 0.05) in all
regions, while tyrosine and arginine were negatively
correlated with MMSE (p < 0.05) (Supplemen-
tary Table 1). When the analysis was performed
using Benton’s visual retention index as the
measure of cognitive performance, tyrosine, L-
DOPA, tryptophan, arginine, and GABA positively
correlated with Benton’s visual retention index
(p < 0.05) (Supplementary Table 1), while dopamine,
aminobutanal, aspartate, and guanidobutanoate were
negatively correlated (p < 0.05). However, only
guanidobutanoate and tryptophan correlated with
the Boston naming score (p < 0.05) (Supplementary
Table 1).
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DISCUSSION
The metabolism of neurotransmitters is an impor-
tant consideration in the pathology of all neurological
diseases. In this study, we measured the metabolism
of three key excitatory neurotransmitters dopamine,
glutamate, and aspartate, as well as three inhibitory
neurotransmitters, serotonin, glycine, and GABA.
We tested to see if any observed changes in the abun-
dance of neurotransmitters was associated with the
asymptomatic AD group, and to determine if spe-
cific brain regions exhibited unique differences in
neurotransmitter metabolism.
Dopaminergic depletion in brains with AD
neuropathology and normal cognition
Dopamine is a catecholamine neurotransmitter
[22, 23], which plays several important roles in
the brain acting via four distinct pathways, the
mesolimbic, mesocortical, nigrostatial, and tuberoin-
fundibular pathways. These pathways are responsible
for regulating mood, and aiding cognitive and
motor function. Impairment of this system poten-
tially causes depression [24], memory loss [25], and
impaired motor control observed in patients with AD.
Dopamine does not cross the blood-brain barrier
and is synthesized in two steps from the essential
amino acid tyrosine, with the initial conversion of
tyrosine to L-DOPA catalyzed by tyrosine hydroxy-
lase (TH) with the subsequent conversion of L-DOPA
to dopamine catalyzed by aromatic amino acid
decarboxylase (AAAD). In the MFG, a compara-
ble reduction in dopamine is observed in both the
asymptomatic and symptomatic AD patients (Fig. 2,
Supplementary Figure 1). In the MFG, tyrosine and
L-DOPA, the precursors of dopamine, are elevated,
with a reduction in the abundance of dopamine also
observed, suggesting a decrease in the abundance or
activity of TH and AAAD.
The activity of both TH and AAAD is inhibited
by alpha-synuclein [26], and has been implicated
in the pathology of several neurodegenerative dis-
eases including Parkinson’s disease [27], AD [28],
and Lewy bodies dementia [27–29]. Studies have also
shown that soluble intraneuronal alpha-synuclein, in
the absence of Lewy body pathology is increased
in abundance by up to two-fold in the brain of
AD patients [30, 31]. This suggests a plausible
molecular mechanism by which alpha-synuclein may
modulate brain dopamine concentrations in AD.
Reduced dopamine could reduce the amount of the
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Fig. 2. Potential modifications to synaptic transmission based on alterations in metabolism associated with Alzheimer’s disease pathogenesis.
A) Effects of decreased dopamine synthesis on synaptic transmission. B) Effects of decreased serotonin synthesis on synaptic transmission.
C) Effects of disrupted GABA metabolism on synaptic transmission. Metabolites or processes shown in red are decreased in abundance, blue
are increased, black were measured but unchanged, and grey were non measured intermediates, solid lines represent metabolic reactions
and dashed lines represent protein-protein interactions. AAAD, aromatic amino acid decarboxylase; ABAD, aminobuteraldehyde dehydro-
genase; AGase, arginase; alpha-syn, alpha-synuclein; GDCase, glutamate decarboxylase; ODase, ornithine decarboxylase; PAT, putrescine
aminotransferase; THL, tyrosine hydroxylase; TM, tryptophan monooxygenase.
neurotransmitter released into the synaptic cleft dur-
ing synaptic transmission leading to impaired signal
transduction (Fig. 2). The data (Table 2) shows that
shifts in dopamine metabolism are greater in the
middle frontal gyrus in the ASYMAD group, suggest-
ing that the changes in dopamine metabolism occur
before memory loss occurs.
Neurotransmission inhibition in the inferior
temporal gyrus in AD
The inhibitory neurotransmitter serotonin and its
precursor tryptophan were measured in this study and
were decreased in the ITG of AD patients (Table 2,
Supplementary Figure 1 N and O). Serotonin is syn-
thesized from the essential amino acid tryptophan by
tryptophan monooxygenase and AAAD. As stated
above, alpha-synuclein, which is increased in the
brains of AD patients [30, 31], has been shown to
inhibit the action of AAAD [26], suggesting a poten-
tial co-mechanism leading to decreased serotonin
synthesis as observed in this study. While serotonin
levels in the AD brain are marginally significant, it is
interesting as recent reports have shown that antide-
pressants such as Trazodone, a serotonin antagonist,
could help maintain neural integrity [32, 33].
Glutamate was also reduced in the ITG of AD
patients; this was surprising as glutamate activa-
tion of N-methyl-D-aspartate (NMDA) on the post
synaptic neuron and its excitotoxicity have long
been implicated in the pathology of AD [34–36].
The impairment of the glutaminergic system in the
brain leads to impairment of a range of neurological
functions, including fast excitatory neurotransmis-
sion [37], memory and learning [38], and long term
potentiation [39–41]. The role of glutamate in AD
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is well known. Memantine, an NMDA antagonist, is
used to treat moderate to severe AD, and has been
shown to have affinity for dopamine receptors which
is interesting in light of this report’s findings [42].
In this study, GABA is increased in abundance
but no change is seen in glutamate levels apart
from a modest shift observed in the ITG. While
increased GABA production could still be com-
ing at least in part from glutamate, the changes
observed in other metabolites associated with GABA
metabolism mean that the alterations may arise
from multiple pathways (Fig. 2). GABA is the
chief inhibitory neurotransmitter in the mammalian
nervous system [43, 44]. It does not cross the blood-
brain barrier [45] and in the brain is predominantly
synthesized from the non-essential amino acid glu-
tamate by the action of glutamate decarboxylase
under standard physiological conditions [46]. How-
ever, GABA can be synthesized via several pathways
from selection precursors, including aminobutanal by
aminobutyraldehyde dehydrogenase [47], succinate
semialdehyde by aminobutyrate aminotransferase
[48], and guanidinobutanoate by guanidinobutyrase
(Supplementary Figure 2). Two alternative GABA
synthetic pathways, both of which start from the
urea cycle, have intermediates that are significantly
reduced in abundance (Supplementary Figure 2) sug-
gesting that they may play a role in the dysregulation
of GABA metabolism.
Regardless of the synthetic source of the increased
abundance of GABA, this combined with the reduc-
tion in glutamate in the ITG (Table 2) can produce
a reduction in their ratio, leading to an inhibitory
environment and a reduction in the transmission of
action potentials. When GABA is released into the
synaptic cleft it binds to a range of transmembrane
receptors on both the pre and post-synaptic neurons
leading to the opening of ion channels allowing the
negatively charged chloride ions to enter and posi-
tively charged potassium ions to escape the neuron
(Fig. 2) [49]. This shift leads to loss of the trans-
membrane potential and hyperpolarization of the cell
membrane, inhibiting action potentials produced by
excitatory neurotransmitters like glutamate.
Strengths and limitations
The main strengths of this study are the use of
samples from the well-characterized BLSA, which
has serial cognitive assessments and detailed neu-
ropathological examination postmortem. This allows
the identification and inclusion of the asymptomatic
group enabling us to relate the observed shifts in
metabolism with the severity of pathology as well as
the expression of symptoms. The analysis of the three
brain regions representing areas that are differentially
susceptible to amyloid and tau pathology to deter-
mine how each of these proteins could be associated
with neurotransmitter metabolism independently.
The main limitation of this study is its relatively
small sample size, which means that our findings
need independent validation. However, there are few
cohorts with the extensive longitudinal cognitive
assessment and postmortem neurological examina-
tion means that identifying a sample set that includes
asymptomatic individuals is difficult.
Another possible limitation of this work is that
neurotransmitters can be unstable and likely to break
down after death, hence postmortem interval (PMI)
(time between death and sample collection) is an
important consideration. The postmortem interval in
the control group is not significantly higher compared
to the asymptomatic and AD groups (Table 1). As
PMI in each of the groups is the same, degradation
of these unstable metabolites should be compara-
ble, meaning that the molecular relative abundances
between groups should be similar.
Conclusion
In conclusion, our results showed decreased levels
in dopamine in brains with pathology from patients
who exhibited no cognitive deficit during life. In AD
brains, neurotransmitter dysregulation was observed
in several pathways and correlated with cognitive
tests in AD. Combined therapeutic approaches that
consider the GABAergic and serotonergic pathways
might be useful as adjunctive treatments in AD.
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